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ABSTRACT 
Twin and genealogy studies suggest a strong genetic component of nephrolithiasis. Likewise, urinary 
traits associated with renal stone formation were found to be highly heritable, even after adjustment for 
demographic, anthropometric and dietary covariates. Recent high-throughput sequencing projects of 
phenotypically well-defined cohorts of stone formers and large genome-wide association studies led to 
the discovery of many new genes associated with kidney stones. The spectrum ranges from infrequent 
but highly penetrant variants (mutations) causing mendelian forms of nephrolithiasis (monogenic traits) 
to common but phenotypically mild variants associated with nephrolithiasis (polygenic traits). About 
two-thirds of the genes currently known to be associated with nephrolithiasis code for membrane 
proteins or enzymes involved in renal tubular transport.  
The thick ascending limb of Henle and connecting tubules are of paramount importance for renal water 
and electrolyte handling, urinary concentration and maintenance of acid-base homeostasis. In most 
instances, pathogenic variants in genes involved in thick ascending limb of Henle and connecting tubule 
function result in phenotypically severe disease, frequently accompanied by nephrocalcinosis with 
progressive CKD and to a variable degree by nephrolithiasis. 
The aim of this article is to review the current knowledge on kidney stone disease associated with 
inherited defects in the thick ascending loop of Henle and the connecting tubules. We also highlight 
recent advances in the field of kidney stone genetics that have implications beyond rare disease, offering 
new insights into the most common type of kidney stone disease, i.e. idiopathic calcium stone disease. 
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INTRODUCTION 
Kidney stone formation depends on dietary, environmental and genetic factors. Familial aggregation of 
kidney stone disease was already recognized in 1874 [1]. A positive family history is present in 20-50 
% of renal stone formers (SF) [2-4] and both twin [5] and genealogy [6] studies revealed a strong 
heritability of nephrolithiasis. The genetics of nephrolithiasis is heterogeneous and complex. Driven by 
technical progress in genomic sequence analysis and bioinformatics, there has been an enormous 
increase of knowledge in the field of kidney stone genetics in the last two decades. The spectrum ranges 
from infrequent but highly penetrant variants (mutations) causing mendelian forms of nephrolithiasis 
(monogenic traits) to common but phenotypically mild variants associated with nephrolithiasis 
(polygenic traits). Genome-wide association studies (GWAS) with large sample sizes up to 300’000 
individuals revealed several variants that are associated with an increased or decreased risk of kidney 
stone disease [7-9]. The clinical relevance and contribution of these common variants to the overall 
burden of kidney stone disease, however, remain unclear. The situation is different at the other end of 
spectrum, the mendelian forms of nephrolithiasis. About 30 monogenetic forms of nephrolithiasis have 
been identified thus far and the list is continuously growing [10,11]. A decade ago, less than 2 % of all 
SF were estimated to have an underlying monogenetic cause [12]. In a recent study with a selected group 
of individuals suffering from recurrent nephrolithiasis or isolated nephrocalcinosis, high throughput 
sequencing revealed a monogenetic cause in 11.4 % of adult cases and 20.8 % of childhood-onset cases 
[11]. Recessive mutations were more frequent among children, dominant disease occurred more 
abundantly in adults. About two-thirds of the genes (~20 out of 30) currently known to be associated 
with monogenetic stone disease code for membrane proteins or enzymes involved in renal tubular 
transport.  
The thick ascending limb of Henle (TALH) and connecting tubules (CNT) have a central role in renal 
water and electrolyte handling as well as in the maintenance of acid-base homeostasis. As such it is not 
surprising that mutations in genes involved in TALH and CT function can result in phenotypically severe 
disease. Mutations in at least 10 genes expressed in these two tubular segments are known to be 
associated with recurrent nephrolithiasis, including Bartter’s syndrome (BS), familial hypomagnesemia 
with hypercalciuria and nephrocalcinosis (FHHNC) and distal renal tubular acidosis (dRTA) [13]. Apart 
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from rare genetic forms of stone disease, the medullary TALH is also involved in the formation of 
interstitial apatite deposits, known as Randall’s plaques, which are thought to represent the starting point 
for Ca oxalate stone formation [14,15]. 
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ANATOMICAL AND PHYSIOLOGICAL ASPECTS 
We will briefly review in this section several anatomical and physiological aspects that are necessary to 
understand the inherited defects in the TALH and CNT leading to secondary nephrolithiasis.  
 
LOOP OF HENLE 
The loop of Henle comprises the descending thin limb, the ascending thin limb, and the thick ascending 
limb. Superficial and midcortical nephrons have a short thin descending limb or may even lack a thin 
descending limb, so that the TALH begins at the hairpin turn. In contrast, juxtamedullary nephrons 
contain a long loop extending deep into the medulla with the TALH beginning at the boundary between 
the inner and outer medulla. Unlike the thin descending limb, the thin ascending limb and the TALH do 
not express aquaporin-1 and hence are water impermeable [16]. Physiological functions of descending 
and ascending thin limbs have been reviewed in detail elsewhere [17]. For the sake of this review, we 
will place special emphasis on the TALH, which is critically involved in fluid and electrolytes 
homeostasis, urine concentration/dilution, acid-base homeostasis, as well as urinary protein composition 
[18]. 
The TALH is responsible for the reabsorption of 25 to 40% of filtered NaCl and thus plays a crucial role 
in the maintenance of extracellular volume [19]. Due to the impermeability to water, the TALH 
contributes to the urinary concentrating mechanism by diluting the luminal fluid, establishing a gradient 
of increasing osmolarity along the medulla via a countercurrent multiplication process [20]. NaCl 
reabsorption occurs through the co-transport of 1 Na, 1 K and 2 Cl ions mediated by NKCC2, a co-
transporter expressed at the apical membrane along the entire TALH (Fig. 1) [21]. This electroneutral 
co-transport is driven by the Na-gradient generated by the Na/K-ATPase on the basolateral membrane 
and can specifically be inhibited by “loop” diuretics such as furosemide or bumetanide [22,23]. The 
proper functioning of NKCC2 also requires apical K channels, mainly renal outer medullary K channels 
(ROMK) and to a lesser extent big K (BK) channels, whose function is to “recycle” K ions back into the 
lumen [24,25]. Without this recycling, the low luminal K content of the TALH would indeed result in a 
severely impaired NKCC2-mediated NaCl transport [26]. On the basolateral side of TALH cells, the 
chloride channels CLC-Ka and CLC-Kb with their associated Barttin subunit mediate electrogenic 
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efflux of Cl ions [27], whereas the electroneutral K-Cl cotransporter KCC4 is responsible for K-
dependent Cl exit (Fig. 1) [28].  
The apical co-transport of 1 Na+, 1 K+ and 2 Cl- ions through NKCC2 coupled to the apical recycling of 
K generates a lumen-positive transepithelial voltage that drives paracellular reabsorption of cations such 
as Na, Mg, and Ca [29]. The TALH reabsorbs 50%-70% of filtered Mg and up to 25% of filtered Ca 
[30,31]. Charge and size selective tight junctions composed of different types of claudins facilitate and 
regulate this paracellular transport [32]. In particular, claudin-16 and claudin-19 critically contribute to 
this task, genetic disruption of claudin-16 or -19 causes urinary Mg and Ca wasting in both mice and 
men [33-36]. Claudin-16 and claudin-19 form a complex with claudin-3 to build a pore for divalent 
cations in the TALH [37]. Claudin-14 interacts with claudin-16 and thereby attenuates Ca permeability 
through this tight junction pores (Fig. 1) [38]. Claudin-14 transcript and protein are upregulated by high 
Ca diet and downregulated by low Ca diet. A second TALH tight junction pore mainly permeable for 
Na is formed by claudin-10b. Conditional TALH claudin-10b KO mice exhibit increased paracellular 
permeabilities of Mg and Ca but greatly decreased Na permeability, resulting in hypermagnesemia, 
hypocalciuria, nephrocalcinosis and polyuria [39]. Together these findings indicate that there are two 
different paracellular permeability pathways in the TALH, a Na-permeable pathway formed by claudin-
10b and a Ca- and Mg-permeable pathway formed by claudin-16 and claudin-19. If one type of claudin 
complex is perturbed or eliminated, the other predominates conferring only its functional permeability 
properties. In support of this notion, deletion of claudin-10b rescues claudin-16 deficient mice from 
hypomagnesemia and hypercalciuria [40]. Double mutant mice display a complete loss of paracellular 
cation selectivity at the level of the TALH with recruitment of downstream compensatory mechanisms. 
The calcium-sensing receptor (CaSR) is strongly expressed at the basolateral membrane of TALH cells, 
and regulates NaCl and Ca transport in this segment [41]. Activation of the CaSR by elevated 
extracellular Ca has been shown to reduce apical NaCl transport via the inhibition of ROMK [42]. This 
mitigates the lumen-positive transepithelial potential necessary for the paracellular transport of Ca, 
resulting in hypercalciuria. However, a recent study reported that inhibition of the CaSR causes 
hypocalciuria without concomitant alteration in NaCl transport, suggesting that the CaSR may primarily 
influence the paracellular transport pathway [43]. Indeed, results from several recent studies 
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demonstrate that the CaSR directly regulates the expression of claudin-14 and claudin-16 
[44,38,45,46,43].  
In addition to their resorptive tasks, TALH cells express and secrete uromodulin (also known as Tamm-
Horsfall protein) into the urine [47]. Uromodulin is the most abundant protein physiologically present 
in urine and regulates blood pressure via modulation of ROMK and NKCC2 activity [48-50], prevents 
tubular crystallization of Ca oxalate [51,52] and also has a protective role against urinary tract infections 
[53].  
 
CONNECTING and COLLECTING TUBULES 
After the TALH, the distal nephron encompasses the distal convoluted tubule (DCT), the connecting 
tubule (CNT) and the collecting duct (CD). With the exception of the rabbit kidney, in which the 
boundaries between these segments are clearly defined, the delineation is gradual in most species [54]. 
The CNT appears thus as a transition segment between the DCT and the CD. The CNT contains CNT-
specific cells, which resemble principal cells of the CD, and intercalated cells. The CD is classically 
divided into three parts: the cortical collecting duct, the outer medullary collecting duct and inner 
medullary collecting duct. As for the CNT, the CD contains principal cells and intercalated cells, which 
are further subdivided in 3 subtypes including type A, type B, and non-A/non-B intercalated cells. The 
CD is a “salt and pepper” type epithelium, with principal cells being the main cell type with intercalated 
cells “sprinkled” throughout [55]. Hereditary defects in type A intercalated cells but not in other CNT 
and CD cells cause kidney stone disease in humans. Type A intercalated cells are found from the late 
DCT to the inner medullary collecting duct and are critical for urinary net acid excretion [56]. They 
exhibit basolateral expression of the Cl /bicarbonate exchanger AE1 and V-ATPase activity at the apical 
membrane (Fig. 2) [54,57]. The V-ATPase consists of two multi-subunit complexes, the V1 (head) and 
V0 (membrane anchored) subunits [58]. The 640 kDa V1 subunit is composed of subunits A, B, C, D, 
E, F, G and H. Mammals have two B subunits, the ubiquitous B2 isoform and the B1 isoform, which is 
restricted to specialized epithelia of the inner ear, epididymis and intercalated cells [59,60]. Protons 
furnished by the cytosolic carbonic anhydrase type II present in type A intercalated cells are translocated 
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against a concentration gradient by the ATP-driven V-ATPase into the urine. Contemporaneous with 
apical proton secretion, carbonic anhydrase liberates bicarbonate ions, which exit basolaterally via AE1.  
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GENETIC DISORDERS OF THE THICK ASCENDING LOOP OF HENLE 
MONOGENETIC DISEASE 
Bartter syndrome 
Antenatal and classical Bartter syndromes constitute a congenital heterogeneous family of salt 
reabsorption disorders, which share common features such as hypokalemic metabolic alkalosis, elevated 
renin and aldosterone levels without hypertension, hypercalciuria, nephrolithiasis and nephrocalcinosis. 
The antenatal form of Bartter syndrome presents with additional severe symptoms including maternal 
polyhydramnios, premature birth, dehydration due to polyuria and early-onset nephrocalcinosis [61]. 
Five genes are currently known to cause Bartter syndrome: Mutations in the SLCA12A1 gene coding for 
the Na, K, 2 Cl cotransporter NKCC2 cause Bartter syndrome type I, mutations in the KCNJ1 gene 
coding for the K channel ROMK cause Bartter syndrome type II, mutations in the CLCNKB gene coding 
for the voltage-gated Cl channel ClC-Kb cause Bartter syndrome type III, mutations in the BSND gene 
coding for barttin cause Bartter syndrome type IV, and mutations in the CASR gene coding for the CaSR 
causes Bartter syndrome type V (Table 1) [62-67]. With the exception of Bartter syndrome type V, 
which is due to a dominant activating mutation of the CaSR, the other types of Bartter syndrome result 
from recessive loss-of-function mutations. 
Mutations in the CLCN5 gene coding for the voltage-gated chloride channel ClC-5 in the proximal 
tubule cause Dent disease and nephrolithiasis and may also be associated with a Bartter-like syndrome 
[68-70]. In addition, a severe but transient form of antenatal Bartter syndrome due to mutations in the 
melanoma-associated antigen D2 (encoded by the X-chromosomal MAGED2 gene) has recently been 
reported [71]. MAGED2 gene mutations are associated with polyhydramnios, prematurity and increased 
perinatal mortality but an association with kidney stones has not been reported. 
In 2002, the first patient with Bartter syndrome and kidney stones was described [72]. The reported 
patient was a 28 year old male with genetically confirmed Bartter syndrome type III. He had 
hypercalciuria but no evidence of nephrocalcinosis, stone analysis results were not reported. In the last 
20 years, several large case-series with Bartter patients were published. In an Italian long-term follow-
up study of 15 patients with Bartter syndrome type I and II, an increased Ca/creatinine ratio was found 
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in 10 of 11 investigated children and all but one child had signs of nephrocalcinosis at diagnosis. 
Nephrolithiasis was not observed at baseline or during a median follow-up of 11 years [73]. In another 
series with 40 patients, all patients with Bartter syndrome type II had evidence of hypercalciuria and 
medullary nephrocalcinosis within the first weeks of life, whereas only two of 20 patients with Bartter 
syndrome type III displayed hypercalciuria and nephrocalcinosis [74]. The prevalence of nephrolithiasis 
was not reported. Similar findings were reported in another study with 52 Bartter patients: 
nephrocalcinosis was present in 31 of 32 cases with Bartter syndromes type I and II but only in two of 
20 patients with Bartter syndrome type III [75]. The prevalence of nephrolithiasis was also not described 
in this study. In a nationwide Korean cohort, Bartter syndrome type III was found to be the most common 
form of Bartter syndrome, affecting 23 of 26 genotyped patients [76]. Hypercalciuria and 
nephrocalcinosis were present in ~60% and ~20% of patients, respectively, but the prevalence of 
nephrolithiasis was not described. In another long-time follow-up study (median follow-up 8.3 years) 
with 42 patients with Bartter syndrome type I to IV , all patients with Bartter syndrome type I and II had 
hypercalciuria and nephrocalcinosis. Out of four children with Bartter syndrome type III for which 
biochemical data were available, three children had hypercalciuria but only one child also displayed 
nephrocalcinosis. Of the four children with Bartter syndrome type IV reported, two were also found to 
have hypercalciuria and nephrocalcinosis [61]. Again, prevalence of nephrolithiasis was not reported. 
The high phenotypic variability of Bartter syndrome type III is well illustrated by a recent large 
retrospective study with 115 patients [77]. Clinical features of the antenatal/neonatal form were found 
in ~30% of patients, features of the classical form in ~45% of patients and features of a Gitelman-like 
form in ~25% of patients. Urinary Ca/creatinine ratio was highest in the antenatal form and lowest in 
the Gitelman-like form. Nephrocalcinosis followed the same distribution pattern with prevalence rates 
of 29.4 % in the antenatal form, 14 % in the classical form and only 3 % in the Gitelman-like form. 
Follow-up data (median follow-up was 8 years) were available in 77 of the 115 patients. Overall, seven 
patients developed nephrolithiasis (two of 26 patients with the antenatal form, five of 35 patients with 
the classical form but none of the 16 patients with the Gitelman-like presentation). The exact distribution 
between symptomatic stone events and asymptomatic stones discovered during imaging, stone 
composition results and urinary risk factors of stone formation other than calciuria were not reported.  
Page 3 of 33 
 
It is remarkable that in the published case-series on Bartter syndrome, prevalence of nephrolithiasis is 
often not reported and if reported, nephrolithiasis seems to be considerably lower than the prevalence of 
nephrocalcinosis. Strinkingly, we have not found a single published case of Bartter syndrome with the 
results of a stone analysis reported. In our own stone clinic, we follow one patient with Bartter syndrome 
and recurrent nephrolithiasis. This currently 27 year old male with a compound heterozygous SLC12A1 
mutation (c.799G>A, p.A267T and c.2752G>A, p.D918N) developed recurrent calcium nephrolithiasis 
at age 24. Two infrared spectroscopy-based stone analyses were performed on two consecutive stones, 
both yielding the same composition:  60 % octa-ca-dihydrogen phosphate and 40 % carbonate apatite. 
Although the patient had mild compensated metabolic alkalosis (venous plasma bicarbonate 33.4 
mmol/L), he was found to be profoundly hypocitraturic (0.03 – 0.06 mmol/24 h), likely due to medullary 
nephrocalcinosis with mild CKD (plasma creatinine 125 - 148 µmol/L) and a urinary acidification deficit 
(24 h urinary pH values between 6.6 and 6.8). Urinary Ca was significantly elevated (8.6 - 8.8 mmol/24 
h), urinary volumes were between 3.1-3.4 l/24 h. In addition, the patient also had a constellation 
compatible with normocalcemic primary hyperparathyroidism with elevated PTH (129 pg/ml), high 
normal ionized plasma Ca (1.21 – 1.29 mmol/l) and low normal plasma P (0.78 – 0.94 mmol/l). The 
association of Bartter syndrome type I and primary hyperparathyroidism has only recently been 
recognized [78,79]. None of the reported six pediatric cases suffered from symptomatic kidney stones 
but one child had radiologic evidence of asymptomatic nephrolithiasis. Cinacalcet and potassium citrate 
improved biochemical abnormalities in these children. As in the reported cases, sestamibi scintigraphy 
and neck MRI failed to reveal a parathyroid adenoma in our patient. The patient was started on cinacalcet 
30 mg twice daily and potassium citrate 30 mmol twice daily, which resulted in a significant rise of 
urinary citrate to 0.87 mmol/24 h and a large drop in urinary Ca excretion to 2.8 mmol/24 h. The patient 
had a last symptomatic stone event 20 months after treatment initiation (22 months after the first stone 
event) and has remained asymptomatic now since 12 months. 
As outlined above, large series suggest a correlation between degree of hypercalciuria and prevalence 
of nephrocalcinosis / nephrolithiasis in Bartter syndrome patients. Factors favoring the development of 
kidney stones in Bartter syndrome remain elusive so far. Indeed, high urinary volume and high urinary 
citrate due to metabolic alkalosis should prevent stone formation. Similarly, reduced Ca reabsorption at 
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the level of the TALH should prevent Randall plaque formation and thus CaOx stone formation. These 
findings raise several questions. DoBartter patients only form stones in the setting of high urinary Ca, 
low urinary citrate and increased urinary pH as in our case ? Are all Bartter patients forming CaP stones 
? What is the site of stone formation (ductal plugging versus growth on plaques) ? Clearly, carefully 
conducted prospective studies with detailed clinical, genetic, biochemical and high-resolution imaging 
data are needed to better understand the pathophysiological mechanisms leading to kidney stone 
formation in Bartter patients. 
 
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis 
The autosomal-recessive disorder familial hypomagnesemia with hypercalciuria and nephrocalcinosis 
(FHHNC) is caused by homozygous mutations in the claudin-16 (alias paracellin-1) and claudin-19 
genes CLDN16 and CLDN19, respectively (Table 1) [33,34]. Symptoms include seizures, tetany, failure 
to thrive, polyuria, recurrent urinary tract infections, nephrolithiasis and CKD with a substantial portion 
of patients eventually progressing to ESRD [80]. The phenotype of CLDN19 mutation is similar to the 
CLDN16 mutation syndrome but affected individuals additionally display ocular involvement (macular 
coloboma, myopia, retinitis pigmentosa, nystagmus and visual loss) [34]. Similar to Bartter syndrome, 
nephrocalcinosis seems to be much more prevalent than nephrolithiasis in FHHNC. While 
nephrocalcinosis is a universal finding in FHHNC patients, nephrolithiasis was reported in 25 % and 42 
% of patients with claudin-16 and claudin-19 mutations, respectively [81,34]. 
CKD progression was found to be unaffected by magnesium salts or thiazide diuretics but early 
treatment with vitamin D and Ca was essential to maintain growth in children [82]. In a more recent 
small cross-over study with four male and four female patients with FHHNC due to homozygous 
CLDN16 mutations, short-time administration of hydrochlorothizide effectively reduced urinary Ca to 
a variable degree without significant alteration of urinary Mg excretion, but long-term treatment data 
are lacking [83]. Interestingly, in larger pedigree analyses, hypercalciuria and nephrolithiasis but not 
nephrocalcinosis or hypomagnesemia were observed in otherwise healthy family members, suggesting 
that pathogenic CLDN16 variants may be associated with “idiopathic” Ca stones [80,84,81]. 
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VARIANTS 
 
Claudin-14 
A GWAS in 3773 SF and 42,510 healthy controls from Iceland and the Netherlands foundcommon 
synonymous variants in the CLDN14 gene encoding claudin-14 to be associated with an increased risk 
for kidney stones and reduced bone mineral density (Table 1) [8]. The synonymous variant rs219780(C) 
was present in a homozygous state in 62 % of the population and confered an estimated 1.64 -fold 
increased risk for the development of kidney stones compared to noncarriers. The rs219780(C) variant 
was also significantly associated with increased urinary Ca and serum parathyroid hormone and reduced 
serum total CO2, but was not associated with serum Ca, P or vitamin D.  
Another study investigated the association of rare variants (allele frequencies <2%) in 40 candidate 
genes in 960 individuals with low and high 24-hour urinary Ca excretion from the Nurses' Health Studies 
I & II and the Health Professionals Follow-up Study [85]. None of the rare gene variants assessed were 
found with increased frequency in the low vs. high urinary Ca groups. The analysis of variants with 
allele frequencies ≥ 2% suggested an association of the non-synonymous CLDN14 variant rs11383113 
(c.11C>T, p.Thr4Met) with lower urinary Ca excretion. The CLDN14 gene variant rs219780, which had 
been reported to increase the risk for kidney stones in the Icelandic and Dutch population, did not 
segregate between the groups with low and high 24-hour urinary Ca excretion [8,85].  In another study 
with 200 kidney SF and 200 healthy controls from the eastern part of India, the two variants rs219777 
and rs219778 in the CLDN14 gene were found to be strongly associated with kidney stone disease, but 
no significant association was found with urinary or serum Ca [86]. A more recent study described the 
association of the CLDN14 gene variant rs78250838:C>T in an intronic cis-regulatory element with 
early-onset hypercalciuria and kidney stones in children [87]. In vitro studies revealed that this variant 
enhances claudin-14 expression, thereby increasing urinary Ca excretion and promoting calcium  stone 
formation.  
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Calcium-sensing receptor 
Vezzoli et al. were the first to report a positive association of the non-synonymous CaSR gene variant 
rs1042636 (p.R990G) in exon 7 with urinary Ca excretion in a cohort of kidney SF [88]. The association 
of this CASR variant with urinary Ca excretion and calcium  nephrolithiasis has been reproduced in other 
ethnic cohorts [86,89]. Several other non-synonymous (rs1801725 and rs1801726), intronic 
(rs17251221 and rs1501899) and 5’ UTR (rs7652589) CASR gene variants have also been associated 
with kidney stone disease in recent years (Table 1) [86,89-94]. 
In a large follow-up GWAS with 5419 kidney stone cases and 279’870 controls in Iceland, additional 
genomic sequence variants associated with kidney stone disease were identified [7]. Relevant for this 
review is the observed association of a novel variant in a regulatory region in the first intron of the CASR 
gene rs7627468(A) that was found to be positively associated with kidney stone disease (odds ratio 
1.16), increased serum total and ionized Ca and decreased 25-hydroxy vitamin D (Table 1).  
 
Uromodulin 
Rare mutations in the UMOD gene cause autosomal-dominant tubulointerstitial kidney disease 
(ADTIK), which is associated with progressive worsening of kidney function, hyperuricemia, gout and 
arterial hypertension but not kidney stones [47]. In a GWAS for CKD in an Icelandic population, a 
common variant rs4293393(T) at the UMOD gene locus was found to be associated with an increased 
risk for the development of CKD and gout but to confer protection against kidney stones (Table 1) [95]. 
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GENETIC DISORDERS OF THE CONNECTING TUBULES 
MONOGENETIC DISEASE 
Distal renal tubular acidosis 
Lightwood provided the first description of congenital distal renal tubular acidosis (dRTA) in an autopsy 
series of six children in 1935 [96]. Five monogenetic forms of dRTA are currently known: autosomal-
recessive and autosomal-dominant mutations in the anion exchanger 1 (AE1, encoded by SLC4A1 gene), 
autosomal-recessive mutations in the B1 and a4 subunits of the V-ATPase (encoded by ATP6V1B1 and 
ATP6V0A4 genes, respectively), autosomal-recessive mutations in the transcription factor Foxi1 
(encoded by the FOXI1 gene) and autosomal-recessive mutations in carbonic anhydrase type II (encoded 
by the CA2 gene) (Table 2) [97-103]. Sensu stricto, CA2 mutations cause a combined proximal-distal 
RTA, also known as type III RTA, but the renal phenotype is very similar to isolated cases of inherited 
dRTA. 
Clinically, diagnosis of dRTA (also known as RTA type I) is straightforward and provocative tests are 
usually not needed. Typical laboratory features include hypokalemia, systemic normal anion gap 
acidosis (in the absence of extrarenal alkali losses), hypocitraturia, hypercalciuria and urinary pH >6.5.  
DRTA can be acquired or inherited, and separation between the two is critical as it will have diagnostic 
and therapeutic consequences (e.g. immunosuppression for Sjögren’s syndrome). Apart from obtaining 
a detailed family history, extrarenal manifestations can be helpful in identifying and differentiating 
inherited cases. In general, phenotype is milder and age of diagnosis significantly later with dominant 
SLC4A1 mutations compared to recessive forms of dRTA [104,105]. Systemic metabolic acidosis may 
even be absent in dominant SLC4A1 mutations, a constellation known as incomplete dRTA [106-108]. 
B1 and a4 subunits of the V-ATPase are expressed in the stria vascularis of the inner ear and almost all 
patients with recessive ATP6V1B1 mutations and about half of patients with recessive ATP6V0A4 
mutations develop progressive, bilateral sensorineural hearing loss [104]. For unknown reasons, onset 
of hearing loss occurs at a younger age and the phenotype is more severe in patients with ATP6V1B1 
mutations [105,109,104]. Sensorineural hearing loss can be accompanied by enlargement of the 
vestibular aqueduct and endolymphatic sac and may contribute to the onset or the progression of hearing 
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impairment [110-112]. SLC4A1 mutations can cause isolated dRTA, isolated hemolytic anemia or both 
[113,114]. DRTA due to dominant SLC4A1 mutations is not associated with hemolytic anemia, unless 
dominant mutations are present in a homozygous or compound heterozygous state [114,113]. Recessive 
SLC4A1 mutations with combined dRTA and hemolytic anemia have been reported in Southeast Asian 
patients, but recessive SLC4A1 mutations can also cause isolated dRTA [115,114]. Patients with 
recessive CA2 mutations can be separated from other forms of inherited dRTA by a wealth of 
characteristic extrarenal features including intracerebral calcifications, psychomotor retardation, 
abnormal teeth with enamel hypoplasia and osteopetrosis, which can be severe, leading to optic nerve 
entrapment and blindness [102,116].  
The sequelae of dRTA are recurrent nephrolithiasis, nephrocalcinosis and low bone mass. While 
nephrocalcinosis is almost a universal finding in inherited dRTA, the prevalence of nephrolithiasis is 
unknown and has not been reported in large cohort studies [105,104]. Hypercalciuria (due to increased 
release of Ca from bone and decreased renal Ca reabsorption), hypocitraturia (due to augmented 
proximal tubular citrate reabsorption) and alkaline urinary pH are the three principal prolithogenic 
factors in dRTA and favor CaP precipitation [117-120]. The typical renal calculus in dRTA consists of 
carbonate apatite and has a characteristic morphology with a smooth aspect and a glazed brown-yellow 
appearance with tiny cracks [121,122]. Nephrocalcinosis is almost a universal finding in inherited dRTA 
and frequently associated with reduced GFR [104]. The pathogenesis of nephrocalcinosis in dRTA is 
unknown but possibly involves the same lithogenic factors that also foster the development of stones. 
Patients with dRTA typically present with low bone mass (exception are patients with CA2 mutations), 
primarily due to reduced bone formation and turnover rates, and to some extent defective mineralization 
and reduced non-collagenous proteins [123-125]. Alkali therapy is the cornerstone of dRTA treatment. 
In children, alkali improves bone turnover and somatic growth [126,127]. In adults with dRTA, alkali 
therapy decreases calciuria, increases citraturia, reduces stone formation, normalizes bone formation 
and increases bone density [128,118,129,125]. K-citrate is preferable over Na-citrate because K-citrate 
tends to reduce calciuria in addition to increasing citraturia, whereas Na-citrate at equimolar doses can 
increase calciuria [128].  
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VARIANTS 
 
V-ATPase B1 subunit 
Impaired urinary acidification capacity in the absence of systemic acidosis is a frequent finding in 
recurrent SF and has been designated “incomplete dRTA” [108,130-133]. There is a positive association 
of kidney stone CaP content and the prevalence of a urinary acidification deficit in SF [134,135]. In 
most SF, the cause of the urinary acidification deficit remains obscure and maybe due to acquired or 
inherited conditions. Recent studies revealed that heterozygous carriers of a recessive ATP6V1B1 
truncation mutation c.1401_1402dupGT; p.F468fsX487 or SF heterozygous for the non-synonymous 
ATP6V1B1 polymorphism c.481G>A; p.E161K exhibit a urinary acidification deficit in the absence of 
systemic acidosis, reduced urinary citrate and an increased prevalence of CaP containing kidney stones 
(Table 2) [136,137]. In an unselected cohort of SF referred for metabolic work-up to a tertiary care stone 
clinic, the prevalence of the ATP6V1B1 c.481G>A;p.E161K polymorphism was 5.8 % [137]. Compound 
heterozygosity or homozygosity for the ATP6V1B1 c.481G>A; p.E161K polymorphism was reported to 
be associated with overt dRTA [138,11]. In vitro studies demonstrated intact integration of p.E161K B1 
subunits into the V-ATPase complex but greatly reduced pump function [139,136]. No evidence for a 
dominant-negative effect of p.E161K B1 subunits was observed in these studies, suggesting 
haploinsufficiency in heterozygous carriers as underlying mechanism. If other known V-ATPase B1 or 
a4 subunit mutations also cause a detectable deficit in urinary acidification in a heterozygous state is 
currently unknown. Thus, it is conceivable but yet unproven that additional allelic variants in ATP6V1B1 
or in other genes associated with urinary net acid excretion are associated with a urinary acidification 
deficit, reduced urinary citrate excretion and an increased risk of CaP stone formation. In mice genetic 
deletion of the type A intercalated cell apical ammonia transporter Rhcg, the basolateral K-Cl- 
cotransporter KCC4 or the basolateral chloride/bicarbonate exchanger SLC26A7 cause dRTA [63-65]. 
To date, however, pathogenic variants in these transporters have not been reported in patients with dRTA 
and nephrolithiasis. 
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CONCLUSIONS 
Recognition of monogenetic forms of nephrolithiasis in the TALH and CNT is of prime clinical 
importance. The phenotype is well defined and traits are highly penetrant, making genetic testing a 
powerful diagnostic tool with prognostic and therapeutic relevance. In contrast, the impact of common, 
phenotypically mild variants in TALH or CNT genes on stone recurrence, disease progression and 
treatment response remains unclear. Thus, genetic testing for these common variants therefore has 
currently no role in the clinical care of patients suffering from kidney stones. 
The identification of patients with inherited forms of nephrolithiasis remains a challenge, the main 
obstacle being differentiation from idiopathic stone disease. A detailed history and thorough clinical 
examination of the patient as well as the alertness of the treating physician are key. Red flags pointing 
to inherited kidney stone disease are early onset of disease, positive family history, consanguinity of 
parents, progressive renal failure, nephrocalcinosis, tubular dysfunction or extrarenal manifestations. 
Diagnosis is greatly facilitated if an expert environment with established collaborations between 
nephrologists, urologists and geneticists is available. With novel and specific treatment options at the 
horizon and a continued high rate of discoveries in the field, the relevance of recognition and diagnosis 
of inherited forms of nephrolithiasis will increase considerably in the next years. 
About half of all inherited disorders of the kidney currently known to be associated with nephrolithiasis 
or nephrocalcinosis localize to the TALH or the CT. Molecular and phenotypic investigations of these 
rare disorders have greatly expanded our knowledge in renal physiology. Nevertheless, our 
understanding of the basic mechanisms leading to stone formation and/or interstitial calcifications in 
these patients remains poor. A large knowledge gap also exists on how to best treat these patients to 
prevent stone recurrence and progression of nephrocalcinosis, and the associated CKD. Clearly, there is 
a dire need for more basic and clinical research efforts in this neglected area. Studying these rare 
monogenetic forms of stone disease offers a unique opportunity to unravel general mechanisms of 
calcium  stone formation and may lead to the development of novel diagnostic and therapeutic strategies 
for SF. 
  
Page 3 of 33 
 
DISCLOSURES 
The authors declare no conflicts of interest. DF has served as a consultant for Otsuka Pharmaceuticals. 
DF has received unrestricted research funding from Novartis, Abbvie and Otsuka Pharmaceuticals.  
  
Page 3 of 33 
 
ACKNOWLEDGEMENTS 
DF was supported by the Swiss National Centre of Competence in Research NCCR TransCure and the 
Swiss National Science Foundation (grants # 31003A_135503, 31003A_152829 and 
33IC30_166785/1).  
  
Page 3 of 33 
 
REFERENCES 
1. Clubbe WH (1874) Family disposition to urinary concretions. Lancet 1:823 
2. Resnick M, Pridgen DB, Goodman HO (1968) Genetic predisposition to formation of 
calcium oxalate renal calculi. N Engl J Med 278 (24):1313-1318 
3. Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1997) Family history and risk of kidney 
stones. J Am Soc Nephrol 8 (10):1568-1573 
4. Guerra A, Ticinesi A, Allegri F, Nouvenne A, Pinelli S, Lauretani F, Maggio M, Cervellin 
G, Borghi L, Meschi T (2017) Calcium urolithiasis course in young stone formers is influenced 
by the strength of family history: results from a retrospective study. Urolithiasis 45 (6):525-533 
5. Goldfarb DS, Fischer ME, Keich Y, Goldberg J (2005) A twin study of genetic and dietary 
influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 
67 (3):1053-1061 
6. Edvardsson VO, Palsson R, Indridason OS, Thorvaldsson S, Stefansson K (2009) Familiality 
of kidney stone disease in Iceland. Scand J Urol Nephrol 43 (5):420-424 
7. Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjornsson G, 
Haraldsdottir E, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Masson G, Holm H, Gudbjartsson 
DF, Thorsteinsdottir U, Indridason OS, Palsson R, Stefansson K (2015) Common and rare 
variants associated with kidney stones and biochemical traits. Nat Commun 6:7975 
8. Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, 
Sulem P, Halldorsson BV, de Vegt F, d'Ancona FC, den Heijer M, Franzson L, Christiansen C, 
Alexandersen P, Rafnar T, Kristjansson K, Sigurdsson G, Kiemeney LA, Bodvarsson M, 
Indridason OS, Palsson R, Kong A, Thorsteinsdottir U, Stefansson K (2009) Sequence variants 
in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41 
(8):926-930 
9. Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, Tsunoda T, Kamatani N, Kohri 
K, Chayama K, Kubo M, Nakamura Y, Matsuda K (2012) A genome-wide association study of 
nephrolithiasis in the Japanese population identifies novel susceptible Loci at 5q35.3, 7p14.3, 
and 13q14.1. PLoS Genet 8 (3):e1002541 
10. Gee HY, Jun I, Braun DA, Lawson JA, Halbritter J, Shril S, Nelson CP, Tan W, Stein D, 
Wassner AJ, Ferguson MA, Gucev Z, Sayer JA, Milosevic D, Baum M, Tasic V, Lee MG, 
Hildebrandt F (2016) Mutations in SLC26A1 Cause Nephrolithiasis. Am J Hum Genet 98 
(6):1228-1234 
11. Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, 
Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, Hildebrandt F (2015) 
Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc 
Nephrol 26 (3):543-551 
12. Griffin DG (2004) A review of the heritability of idiopathic nephrolithiasis. J Clin Pathol 
57 (8):793-796 
13. Mohebbi N, Ferraro PM, Gambaro G, Unwin R (2017) Tubular and genetic disorders 
associated with kidney stones. Urolithiasis 45 (1):127-137 
14. Randall A (1936) An hypothesis for the origin of renal calculus. New England Journal of 
Medicine 214 (6):234-242 
15. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, 
Kuo RL, Grynpas M (2003) Randall's plaque of patients with nephrolithiasis begins in basement 
membranes of thin loops of Henle. J Clin Invest 111 (5):607-616 
16. Nielsen S, Pallone T, Smith BL, Christensen EI, Agre P, Maunsbach AB (1995) Aquaporin-
1 water channels in short and long loop descending thin limbs and in descending vasa recta in 
rat kidney. Am J Physiol 268 (6 Pt 2):F1023-1037. doi:10.1152/ajprenal.1995.268.6.F1023 
Page 3 of 33 
 
17. Pannabecker TL (2012) Structure and function of the thin limbs of the loop of Henle. Compr 
Physiol 2 (3):2063-2086. doi:10.1002/cphy.c110019 
18. Mount DB (2014) Thick ascending limb of the loop of Henle. Clin J Am Soc Nephrol 9 
(11):1974-1986. doi:10.2215/CJN.04480413 
19. Greger R (1985) Ion transport mechanisms in thick ascending limb of Henle's loop of 
mammalian nephron. Physiol Rev 65 (3):760-797. doi:10.1152/physrev.1985.65.3.760 
20. Dantzler WH, Layton AT, Layton HE, Pannabecker TL (2014) Urine-concentrating 
mechanism in the inner medulla: function of the thin limbs of the loops of Henle. Clin J Am 
Soc Nephrol 9 (10):1781-1789. doi:10.2215/CJN.08750812 
21. Castrop H, Schiessl IM (2014) Physiology and pathophysiology of the renal Na-K-2Cl 
cotransporter (NKCC2). Am J Physiol Renal Physiol 307 (9):F991-F1002. 
doi:10.1152/ajprenal.00432.2014 
22. Hebert SC, Andreoli TE (1984) Control of NaCl transport in the thick ascending limb. Am 
J Physiol 246 (6 Pt 2):F745-756. doi:10.1152/ajprenal.1984.246.6.F745 
23. Burg M, Stoner L, Cardinal J, Green N (1973) Furosemide effect on isolated perfused 
tubules. Am J Physiol 225 (1):119-124. doi:10.1152/ajplegacy.1973.225.1.119 
24. Wang WH (1994) Two types of K+ channel in thick ascending limb of rat kidney. Am J 
Physiol 267 (4 Pt 2):F599-605. doi:10.1152/ajprenal.1994.267.4.F599 
25. Lu M, Wang T, Yan Q, Wang W, Giebisch G, Hebert SC (2004) ROMK is required for 
expression of the 70-pS K channel in the thick ascending limb. Am J Physiol Renal Physiol 286 
(3):F490-495. doi:10.1152/ajprenal.00305.2003 
26. Greger R, Schlatter E (1981) Presence of luminal K+, a prerequisite for active NaCl 
transport in the cortical thick ascending limb of Henle's loop of rabbit kidney. Pflugers Arch 
392 (1):92-94 
27. Palmer LG, Frindt G (2006) Cl- channels of the distal nephron. Am J Physiol Renal Physiol 
291 (6):F1157-1168. doi:10.1152/ajprenal.00496.2005 
28. Mercado A, Song L, Vazquez N, Mount DB, Gamba G (2000) Functional comparison of 
the K+-Cl- cotransporters KCC1 and KCC4. J Biol Chem 275 (39):30326-30334. 
doi:10.1074/jbc.M003112200 
29. Hebert SC, Andreoli TE (1986) Ionic conductance pathways in the mouse medullary thick 
ascending limb of Henle. The paracellular pathway and electrogenic Cl- absorption. J Gen 
Physiol 87 (4):567-590 
30. de Baaij JH, Hoenderop JG, Bindels RJ (2015) Magnesium in man: implications for health 
and disease. Physiol Rev 95 (1):1-46. doi:10.1152/physrev.00012.2014 
31. Moor MB, Bonny O (2016) Ways of calcium reabsorption in the kidney. Am J Physiol 
Renal Physiol 310 (11):F1337-1350. doi:10.1152/ajprenal.00273.2015 
32. Gong Y, Hou J (2017) Claudins in barrier and transport function-the kidney. Pflugers Arch 
469 (1):105-113. doi:10.1007/s00424-016-1906-6 
33. Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, 
Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP (1999) 
Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 
285 (5424):103-106 
34. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzthum H, 
Suzuki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Ariceta G, 
Cano F, Enriquez R, Juppner H, Bakkaloglu SA, Hediger MA, Gallati S, Neuhauss SC, 
Nurnberg P, Weber S (2006) Mutations in the tight-junction gene claudin 19 (CLDN19) are 
associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J 
Hum Genet 79 (5):949-957. doi:10.1086/508617 
35. Hou J, Shan Q, Wang T, Gomes AS, Yan Q, Paul DL, Bleich M, Goodenough DA (2007) 
Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem 
282 (23):17114-17122. doi:10.1074/jbc.M700632200 
Page 3 of 33 
 
36. Hou J, Renigunta A, Gomes AS, Hou M, Paul DL, Waldegger S, Goodenough DA (2009) 
Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for 
renal reabsorption of magnesium. Proc Natl Acad Sci U S A 106 (36):15350-15355. 
doi:10.1073/pnas.0907724106 
37. Plain A, Alexander RT (2018) Claudins and nephrolithiasis. Curr Opin Nephrol Hypertens 
38. Gong Y, Renigunta V, Himmerkus N, Zhang J, Renigunta A, Bleich M, Hou J (2012) 
Claudin-14 regulates renal Ca(+)(+) transport in response to CaSR signalling via a novel 
microRNA pathway. EMBO J 31 (8):1999-2012. doi:10.1038/emboj.2012.49 
39. Breiderhoff T, Himmerkus N, Stuiver M, Mutig K, Will C, Meij IC, Bachmann S, Bleich 
M, Willnow TE, Muller D (2012) Deletion of claudin-10 (Cldn10) in the thick ascending limb 
impairs paracellular sodium permeability and leads to hypermagnesemia and nephrocalcinosis. 
Proc Natl Acad Sci U S A 109 (35):14241-14246. doi:10.1073/pnas.1203834109 
40. Breiderhoff T, Himmerkus N, Drewell H, Plain A, Gunzel D, Mutig K, Willnow TE, Muller 
D, Bleich M (2018) Deletion of claudin-10 rescues claudin-16-deficient mice from 
hypomagnesemia and hypercalciuria. Kidney Int 93 (3):580-588. 
doi:10.1016/j.kint.2017.08.029 
41. Toka HR, Pollak MR, Houillier P (2015) Calcium Sensing in the Renal Tubule. Physiology 
(Bethesda) 30 (4):317-326. doi:10.1152/physiol.00042.2014 
42. Wang WH, Lu M, Hebert SC (1996) Cytochrome P-450 metabolites mediate extracellular 
Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 271 (1 Pt 1):C103-
111. doi:10.1152/ajpcell.1996.271.1.C103 
43. Loupy A, Ramakrishnan SK, Wootla B, Chambrey R, de la Faille R, Bourgeois S, Bruneval 
P, Mandet C, Christensen EI, Faure H, Cheval L, Laghmani K, Collet C, Eladari D, Dodd RH, 
Ruat M, Houillier P (2012) PTH-independent regulation of blood calcium concentration by the 
calcium-sensing receptor. J Clin Invest 122 (9):3355-3367. doi:10.1172/JCI57407 
44. Dimke H, Desai P, Borovac J, Lau A, Pan W, Alexander RT (2013) Activation of the 
Ca(2+)-sensing receptor increases renal claudin-14 expression and urinary Ca(2+) excretion. 
Am J Physiol Renal Physiol 304 (6):F761-769. doi:10.1152/ajprenal.00263.2012 
45. Gong Y, Hou J (2014) Claudin-14 underlies Ca(+)(+)-sensing receptor-mediated Ca(+)(+) 
metabolism via NFAT-microRNA-based mechanisms. J Am Soc Nephrol 25 (4):745-760. 
doi:10.1681/ASN.2013050553 
46. Toka HR, Al-Romaih K, Koshy JM, DiBartolo S, 3rd, Kos CH, Quinn SJ, Curhan GC, 
Mount DB, Brown EM, Pollak MR (2012) Deficiency of the calcium-sensing receptor in the 
kidney causes parathyroid hormone-independent hypocalciuria. J Am Soc Nephrol 23 
(11):1879-1890. doi:10.1681/ASN.2012030323 
47. Devuyst O, Olinger E, Rampoldi L (2017) Uromodulin: from physiology to rare and 
complex kidney disorders. Nat Rev Nephrol 13 (9):525-544 
48. Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, Citterio L, Demaretz S, 
Trevisani F, Ristagno G, Glaudemans B, Laghmani K, Dell'Antonio G, team S, Loffing J, 
Rastaldi MP, Manunta P, Devuyst O, Rampoldi L (2013) Common noncoding UMOD gene 
variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin 
expression. Nat Med 19 (12):1655-1660. doi:10.1038/nm.3384 
49. Mutig K, Kahl T, Saritas T, Godes M, Persson P, Bates J, Raffi H, Rampoldi L, Uchida S, 
Hille C, Dosche C, Kumar S, Castaneda-Bueno M, Gamba G, Bachmann S (2011) Activation 
of the bumetanide-sensitive Na+,K+,2Cl- cotransporter (NKCC2) is facilitated by Tamm-
Horsfall protein in a chloride-sensitive manner. J Biol Chem 286 (34):30200-30210. 
doi:10.1074/jbc.M111.222968 
50. Renigunta A, Renigunta V, Saritas T, Decher N, Mutig K, Waldegger S (2011) Tamm-
Horsfall glycoprotein interacts with renal outer medullary potassium channel ROMK2 and 
regulates its function. J Biol Chem 286 (3):2224-2235. doi:10.1074/jbc.M110.149880 
Page 3 of 33 
 
51. Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR (2004) Tamm-Horsfall protein 
is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney 
Int 66 (3):1159-1166. doi:10.1111/j.1523-1755.2004.00867.x 
52. Liu Y, Mo L, Goldfarb DS, Evan AP, Liang F, Khan SR, Lieske JC, Wu XR (2010) 
Progressive renal papillary calcification and ureteral stone formation in mice deficient for 
Tamm-Horsfall protein. Am J Physiol Renal Physiol 299 (3):F469-478. 
doi:10.1152/ajprenal.00243.2010 
53. Garimella PS, Bartz TM, Ix JH, Chonchol M, Shlipak MG, Devarajan P, Bennett MR, 
Sarnak MJ (2017) Urinary Uromodulin and Risk of Urinary Tract Infections: The 
Cardiovascular Health Study. Am J Kidney Dis 69 (6):744-751 
54. Roy A, Al-bataineh MM, Pastor-Soler NM (2015) Collecting duct intercalated cell function 
and regulation. Clin J Am Soc Nephrol 10 (2):305-324. doi:10.2215/CJN.08880914 
55. Sampogna RV, Al-Awqati Q (2013) Salt and pepper distribution of cell types in the 
collecting duct. J Am Soc Nephrol 24 (2):163-165. doi:10.1681/ASN.2012121183 
56. Madsen KM, Verlander JW, Tisher CC (1988) Relationship between structure and function 
in distal tubule and collecting duct. J Electron Microsc Tech 9 (2):187-208. 
doi:10.1002/jemt.1060090206 
57. Wall SM, Weinstein AM (2013) Cortical distal nephron Cl(-) transport in volume 
homeostasis and blood pressure regulation. Am J Physiol Renal Physiol 305 (4):F427-438. 
doi:10.1152/ajprenal.00022.2013 
58. Smith AN, Lovering RC, Futai M, Takeda J, Brown D, Karet FE (2003) Revised 
nomenclature for mammalian vacuolar-type H+ -ATPase subunit genes. Mol Cell 12 (4):801-
803 
59. Miller RL, Zhang P, Smith M, Beaulieu V, Paunescu TG, Brown D, Breton S, Nelson RD 
(2005) V-ATPase B1-subunit promoter drives expression of EGFP in intercalated cells of 
kidney, clear cells of epididymis and airway cells of lung in transgenic mice. Am J Physiol Cell 
Physiol 288 (5):C1134-1144 
60. Breton S, Brown D (2013) Regulation of luminal acidification by the V-ATPase. 
Physiology (Bethesda) 28 (5):318-329. doi:10.1152/physiol.00007.2013 
61. Brochard K, Boyer O, Blanchard A, Loirat C, Niaudet P, Macher MA, Deschenes G, 
Bensman A, Decramer S, Cochat P, Morin D, Broux F, Caillez M, Guyot C, Novo R, 
Jeunemaitre X, Vargas-Poussou R (2009) Phenotype-genotype correlation in antenatal and 
neonatal variants of Bartter syndrome. Nephrol Dial Transplant 24 (5):1455-1464. 
doi:10.1093/ndt/gfn689 
62. Stechman MJ, Loh NY, Thakker RV (2009) Genetic causes of hypercalciuric 
nephrolithiasis. Pediatr Nephrol 24 (12):2321-2332. doi:10.1007/s00467-008-0807-0 
63. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad 
SA, Lifton RP (1996) Genetic heterogeneity of Bartter's syndrome revealed by mutations in the 
K+ channel, ROMK. Nat Genet 14 (2):152-156 
64. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP (1996) Bartter's 
syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl 
cotransporter NKCC2. Nat Genet 13 (2):183-188 
65. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, 
Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, 
Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP (1997) 
Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 
17 (2):171-178 
66. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, 
Fujita T (2002) Association between activating mutations of calcium-sensing receptor and 
Bartter's syndrome. Lancet 360 (9334):692-694 
Page 3 of 33 
 
67. Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, 
Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NV, 
Antignac C, Sudbrak R, Kispert A, Hildebrandt F (2001) Mutation of BSND causes Bartter 
syndrome with sensorineural deafness and kidney failure. Nat Genet 29 (3):310-314 
68. Besbas N, Ozaltin F, Jeck N, Seyberth H, Ludwig M (2005) CLCN5 mutation (R347X) 
associated with hypokalaemic metabolic alkalosis in a Turkish child: an unusual presentation 
of Dent's disease. Nephrol Dial Transplant 20 (7):1476-1479. doi:10.1093/ndt/gfh799 
69. Okamoto T, Tajima T, Hirayama T, Sasaki S (2012) A patient with Dent disease and 
features of Bartter syndrome caused by a novel mutation of CLCN5. Eur J Pediatr 171 (2):401-
404. doi:10.1007/s00431-011-1578-3 
70. Bogdanovic R, Draaken M, Toromanovic A, Dordevic M, Stajic N, Ludwig M (2010) A 
novel CLCN5 mutation in a boy with Bartter-like syndrome and partial growth hormone 
deficiency. Pediatr Nephrol 25 (11):2363-2368. doi:10.1007/s00467-010-1615-x 
71. Laghmani K, Beck BB, Yang SS, Seaayfan E, Wenzel A, Reusch B, Vitzthum H, Priem D, 
Demaretz S, Bergmann K, Duin LK, Gobel H, Mache C, Thiele H, Bartram MP, Dombret C, 
Altmuller J, Nurnberg P, Benzing T, Levtchenko E, Seyberth HW, Klaus G, Yigit G, Lin SH, 
Timmer A, de Koning TJ, Scherjon SA, Schlingmann KP, Bertrand MJ, Rinschen MM, de 
Backer O, Konrad M, Komhoff M (2016) Polyhydramnios, Transient Antenatal Bartter's 
Syndrome, and MAGED2 Mutations. N Engl J Med 374 (19):1853-1863 
72. Colussi G, De Ferrari ME, Tedeschi S, Prandoni S, Syren ML, Civati G (2002) Bartter 
syndrome type 3: an unusual cause of nephrolithiasis. Nephrol Dial Transplant 17 (3):521-523 
73. Puricelli E, Bettinelli A, Borsa N, Sironi F, Mattiello C, Tammaro F, Tedeschi S, Bianchetti 
MG, Italian Collaborative Group for Bartter S (2010) Long-term follow-up of patients with 
Bartter syndrome type I and II. Nephrol Dial Transplant 25 (9):2976-2981. 
doi:10.1093/ndt/gfq119 
74. Jeck N, Konrad M, Hess M, Seyberth HW (2000) The diuretic- and Bartter-like salt-losing 
tubulopathies. Nephrol Dial Transplant 15 Suppl 6:19-20 
75. Peters M, Jeck N, Reinalter S, Leonhardt A, Tonshoff B, Klaus GG, Konrad M, Seyberth 
HW (2002) Clinical presentation of genetically defined patients with hypokalemic salt-losing 
tubulopathies. Am J Med 112 (3):183-190 
76. Lee BH, Cho HY, Lee H, Han KH, Kang HG, Ha IS, Lee JH, Park YS, Shin JI, Lee DY, 
Kim SY, Choi Y, Cheong HI (2012) Genetic basis of Bartter syndrome in Korea. Nephrol Dial 
Transplant 27 (4):1516-1521. doi:10.1093/ndt/gfr475 
77. Seys E, Andrini O, Keck M, Mansour-Hendili L, Courand PY, Simian C, Deschenes G, 
Kwon T, Bertholet-Thomas A, Bobrie G, Borde JS, Bourdat-Michel G, Decramer S, Cailliez 
M, Krug P, Cozette P, Delbet JD, Dubourg L, Chaveau D, Fila M, Jourde-Chiche N, 
Knebelmann B, Lavocat MP, Lemoine S, Djeddi D, Llanas B, Louillet F, Merieau E, Mileva 
M, Mota-Vieira L, Mousson C, Nobili F, Novo R, Roussey-Kesler G, Vrillon I, Walsh SB, 
Teulon J, Blanchard A, Vargas-Poussou R (2017) Clinical and Genetic Spectrum of Bartter 
Syndrome Type 3. J Am Soc Nephrol 28 (8):2540-2552. doi:10.1681/ASN.2016101057 
78. Li D, Tian L, Hou C, Kim CE, Hakonarson H, Levine MA (2016) Association of Mutations 
in SLC12A1 Encoding the NKCC2 Cotransporter With Neonatal Primary 
Hyperparathyroidism. J Clin Endocrinol Metab 101 (5):2196-2200 
79. Wongsaengsak S, Vidmar AP, Addala A, Kamil ES, Sequeira P, Fass B, Pitukcheewanont 
P (2017) A novel SLC12A1 gene mutation associated with hyperparathyroidism, 
hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients. Bone 
97:121-125 
80. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, 
Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Scharer 
K, Seyberth HW, Konrad M (2001) Novel paracellin-1 mutations in 25 families with familial 
Page 3 of 33 
 
hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 12 (9):1872-
1881 
81. Praga M, Vara J, Gonzalez-Parra E, Andres A, Alamo C, Araque A, Ortiz A, Rodicio JL 
(1995) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int 47 
(5):1419-1425 
82. Wolf MT, Dotsch J, Konrad M, Boswald M, Rascher W (2002) Follow-up of five patients 
with FHHNC due to mutations in the Paracellin-1 gene. Pediatr Nephrol 17 (8):602-608 
83. Zimmermann B, Plank C, Konrad M, Stohr W, Gravou-Apostolatou C, Rascher W, Dotsch 
J (2006) Hydrochlorothiazide in CLDN16 mutation. Nephrol Dial Transplant 21 (8):2127-
2132. doi:10.1093/ndt/gfl144 
84. Tasic V, Dervisov D, Koceva S, Weber S, Konrad M (2005) Hypomagnesemia with 
hypercalciuria and nephrocalcinosis: case report and a family study. Pediatr Nephrol 20 
(7):1003-1006 
85. Toka HR, Genovese G, Mount DB, Pollak MR, Curhan GC (2013) Frequency of rare allelic 
variation in candidate genes among individuals with low and high urinary calcium excretion. 
PLoS One 8 (8):e71885. doi:10.1371/journal.pone.0071885 
86. Guha M, Bankura B, Ghosh S, Pattanayak AK, Ghosh S, Pal DK, Puri A, Kundu AK, Das 
M (2015) Polymorphisms in CaSR and CLDN14 Genes Associated with Increased Risk of 
Kidney Stone Disease in Patients from the Eastern Part of India. PLoS One 10 (6):e0130790. 
doi:10.1371/journal.pone.0130790 
87. Ure ME, Heydari E, Pan W, Ramesh A, Rehman S, Morgan C, Pinsk M, Erickson R, 
Herrmann JM, Dimke H, Cordat E, Lemaire M, Walter M, Alexander RT (2017) A variant in a 
cis-regulatory element enhances claudin-14 expression and is associated with pediatric-onset 
hypercalciuria and kidney stones. Hum Mutat 38 (6):649-657. doi:10.1002/humu.23202 
88. Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, Franceschelli F, Malentacchi C, 
Porfirio B, Adamo D, Terranegra A, Falchetti A, Cusi D, Bianchi G, Brandi ML (2002) 
Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming 
patients. J Am Soc Nephrol 13 (10):2517-2523 
89. Ding Q, Fan B, Shi Y, Fan Z, Ding L, Li F, Tu W, Jin X, Qin C, Cao Q, Yuan Q, Wang J, 
Ouyang J (2017) Calcium-Sensing Receptor Genetic Polymorphisms and Risk of Developing 
Nephrolithiasis in a Chinese Population. Urol Int 99 (3):331-337 
90. Vezzoli G, Terranegra A, Arcidiacono T, Gambaro G, Milanesi L, Mosca E, Soldati L 
(2010) Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor 
gene regulatory region. Nephrol Dial Transplant 25 (7):2245-2252 
91. Vezzoli G, Terranegra A, Aloia A, Arcidiacono T, Milanesi L, Mosca E, Mingione A, Spotti 
D, Cusi D, Hou J, Hendy GN, Soldati L, Paloschi V, Dogliotti E, Brasacchio C, Dell'Antonio 
G, Montorsi F, Bertini R, Bellinzoni P, Guazzoni G, Borghi L, Guerra A, Allegri F, Ticinesi A, 
Meschi T, Nouvenne A, Lupo A, Fabris A, Gambaro G, Strazzullo P, Rendina D, De Filippo 
G, Brandi ML, Croppi E, Cianferotti L, Trinchieri A, Caudarella R, Cupisti A, Anglani F, Del 
Prete D (2013) Decreased transcriptional activity of calcium-sensing receptor gene promoter 1 
is associated with calcium nephrolithiasis. J Clin Endocrinol Metab 98 (9):3839-3847 
92. Shakhssalim N, Kazemi B, Basiri A, Houshmand M, Pakmanesh H, Golestan B, Eilanjegh 
AF, Kashi AH, Kilani M, Azadvari M (2010) Association between calcium-sensing receptor 
gene polymorphisms and recurrent calcium kidney stone disease: a comprehensive gene 
analysis. Scand J Urol Nephrol 44 (6):406-412 
93. Hamilton DC, Grover VK, Smith CA, Cole DE (2009) Heterogeneous disease modeling for 
Hardy-Weinberg disequilibrium in case-control studies: application to renal stones and 
calcium-sensing receptor polymorphisms. Ann Hum Genet 73 (2):176-183 
94. Chou YH, Woon PY, Chen WC, Hsu YW, Chang JM, Hwang DY, Chiu YC, Kuo HC, 
Chang WP, Hou MF, Liu ME, Chang JG, Chang WC (2011) A genetic polymorphism 
Page 3 of 33 
 
(rs17251221) in the calcium-sensing receptor gene (CASR) is associated with stone multiplicity 
in calcium nephrolithiasis. PLoS One 6 (9):e25227 
95. Gudbjartsson DF, Holm H, Indridason OS, Thorleifsson G, Edvardsson V, Sulem P, de 
Vegt F, d'Ancona FC, den Heijer M, Wetzels JF, Franzson L, Rafnar T, Kristjansson K, 
Bjornsdottir US, Eyjolfsson GI, Kiemeney LA, Kong A, Palsson R, Thorsteinsdottir U, 
Stefansson K (2010) Association of variants at UMOD with chronic kidney disease and kidney 
stones-role of age and comorbid diseases. PLoS Genet 6 (7):e1001039 
96. Lightwood R (1935) Communication no. 1. Arch Dis Child 10:205 
97. Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, Rodriguez-Soriano J, 
Santos F, Cremers CW, Di Pietro A, Hoffbrand BI, Winiarski J, Bakkaloglu A, Ozen S, 
Dusunsel R, Goodyer P, Hulton SA, Wu DK, Skvorak AB, Morton CC, Cunningham MJ, Jha 
V, Lifton RP (1999) Mutations in the gene encoding B1 subunit of H+-ATPase cause renal 
tubular acidosis with sensorineural deafness. Nat Genet 21 (1):84-90 
98. Smith AN, Skaug J, Choate KA, Nayir A, Bakkaloglu A, Ozen S, Hulton SA, Sanjad SA, 
Al-Sabban EA, Lifton RP, Scherer SW, Karet FE (2000) Mutations in ATP6N1B, encoding a 
new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis 
with preserved hearing. Nat Genet 26 (1):71-75 
99. Enerback S, Nilsson D, Edwards N, Heglind M, Alkanderi S, Ashton E, Deeb A, Kokash 
FEB, Bakhsh ARA, Van't Hoff W, Walsh SB, D'Arco F, Daryadel A, Bourgeois S, Wagner 
CA, Kleta R, Bockenhauer D, Sayer JA (2018) Acidosis and Deafness in Patients with 
Recessive Mutations in FOXI1. J Am Soc Nephrol 29 (3):1041-1048 
100. Karet FE, Gainza FJ, Gyory AZ, Unwin RJ, Wrong O, Tanner MJ, Nayir A, Alpay H, 
Santos F, Hulton SA, Bakkaloglu A, Ozen S, Cunningham MJ, di Pietro A, Walker WG, Lifton 
RP (1998) Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal 
dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci U S A 
95 (11):6337-6342 
101. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE (1983) Carbonic anhydrase 
II deficiency identified as the primary defect in the autosomal recessive syndrome of 
osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A 
80 (9):2752-2756 
102. Sly WS, Whyte MP, Sundaram V, Tashian RE, Hewett-Emmett D, Guibaud P, Vainsel M, 
Baluarte HJ, Gruskin A, Al-Mosawi M, et al. (1985) Carbonic anhydrase II deficiency in 12 
families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and 
cerebral calcification. N Engl J Med 313 (3):139-145 
103. Mohebbi N, Wagner CA (2018) Pathophysiology, diagnosis and treatment of inherited 
distal renal tubular acidosis. J Nephrol 31 (4):511-522 
104. Palazzo V, Provenzano A, Becherucci F, Sansavini G, Mazzinghi B, Orlandini V, Giunti 
L, Roperto RM, Pantaleo M, Artuso R, Andreucci E, Bargiacchi S, Traficante G, Stagi S, Murer 
L, Benetti E, Emma F, Giordano M, Rivieri F, Colussi G, Penco S, Manfredini E, Caruso MR, 
Garavelli L, Andrulli S, Vergine G, Miglietti N, Mancini E, Malaventura C, Percesepe A, 
Grosso E, Materassi M, Romagnani P, Giglio S (2017) The genetic and clinical spectrum of a 
large cohort of patients with distal renal tubular acidosis. Kidney Int 91 (5):1243-1255 
105. Vargas-Poussou R, Houillier P, Le Pottier N, Strompf L, Loirat C, Baudouin V, Macher 
MA, Dechaux M, Ulinski T, Nobili F, Eckart P, Novo R, Cailliez M, Salomon R, Nivet H, 
Cochat P, Tack I, Fargeot A, Bouissou F, Kesler GR, Lorotte S, Godefroid N, Layet V, Morin 
G, Jeunemaitre X, Blanchard A (2006) Genetic investigation of autosomal recessive distal renal 
tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the 
ATP6V0A4 gene. J Am Soc Nephrol 17 (5):1437-1443 
106. Rysava R, Tesar V, Jirsa M, Jr., Brabec V, Jarolim P (1997) Incomplete distal renal tubular 
acidosis coinherited with a mutation in the band 3 (AE1) gene. Nephrol Dial Transplant 12 
(9):1869-1873 
Page 3 of 33 
 
107. Bruce LJ, Cope DL, Jones GK, Schofield AE, Burley M, Povey S, Unwin RJ, Wrong O, 
Tanner MJ (1997) Familial distal renal tubular acidosis is associated with mutations in the red 
cell anion exchanger (Band 3, AE1) gene. J Clin Invest 100 (7):1693-1707 
108. Wrong O, Davies HE (1959) The excretion of acid in renal disease. Q J Med 28 (110):259-
313 
109. Escobar LI, Simian C, Treard C, Hayek D, Salvador C, Guerra N, Matos M, Medeiros M, 
Enciso S, Camargo MD, Vargas-Poussou R (2016) Mutations in ATP6V1B1 and ATP6V0A4 
genes cause recessive distal renal tubular acidosis in Mexican families. Mol Genet Genomic 
Med 4 (3):303-311 
110. Berrettini S, Neri E, Forli F, Panconi M, Massimetti M, Ravecca F, Sellari-Franceschini 
S, Bartolozzi C (2001) Large vestibular aqueduct in distal renal tubular acidosis. High-
resolution MR in three cases. Acta Radiol 42 (3):320-322 
111. Berrettini S, Forli F, Franceschini SS, Ravecca F, Massimetti M, Neri E (2002) Distal 
renal tubular acidosis associated with isolated large vestibular aqueduct and sensorineural 
hearing loss. Ann Otol Rhinol Laryngol 111 (5 Pt 1):385-391 
112. Berrettini S, Forli F, Bogazzi F, Neri E, Salvatori L, Casani AP, Franceschini SS (2005) 
Large vestibular aqueduct syndrome: audiological, radiological, clinical, and genetic features. 
Am J Otolaryngol 26 (6):363-371 
113. Batlle D, Haque SK (2012) Genetic causes and mechanisms of distal renal tubular acidosis. 
Nephrol Dial Transplant 27 (10):3691-3704 
114. Alper SL (2010) Familial renal tubular acidosis. J Nephrol 23 Suppl 16:S57-76 
115. Bruce LJ, Wrong O, Toye AM, Young MT, Ogle G, Ismail Z, Sinha AK, McMaster P, 
Hwaihwanje I, Nash GB, Hart S, Lavu E, Palmer R, Othman A, Unwin RJ, Tanner MJ (2000) 
Band 3 mutations, renal tubular acidosis and South-East Asian ovalocytosis in Malaysia and 
Papua New Guinea: loss of up to 95% band 3 transport in red cells. Biochem J 350 Pt 1:41-51 
116. Awad M, Al-Ashwal AA, Sakati N, Al-Abbad AA, Bin-Abbas BS (2002) Long-term 
follow up of carbonic anhydrase II deficiency syndrome. Saudi Med J 23 (1):25-29 
117. Goodman AD, Lemann J, Jr., Lennon EJ, Relman AS (1965) Production, Excretion, and 
Net Balance of Fixed Acid in Patients with Renal Acidosis. J Clin Invest 44:495-506 
118. Preminger GM, Sakhaee K, Pak CY (1987) Hypercalciuria and altered intestinal calcium 
absorption occurring independently of vitamin D in incomplete distal renal tubular acidosis. 
Metabolism 36 (2):176-179 
119. Bushinsky DA, Frick KK (2000) The effects of acid on bone. Curr Opin Nephrol 
Hypertens 9 (4):369-379 
120. Alexander RT, Cordat E, Chambrey R, Dimke H, Eladari D (2016) Acidosis and Urinary 
Calcium Excretion: Insights from Genetic Disorders. J Am Soc Nephrol 27 (12):3511-3520 
121. Daudon M, Bouzidi H, Bazin D (2010) Composition and morphology of phosphate stones 
and their relation with etiology. Urol Res 38 (6):459-467 
122. Dessombz A, Letavernier E, Haymann JP, Bazin D, Daudon M (2015) Calcium phosphate 
stone morphology can reliably predict distal renal tubular acidosis. J Urol 193 (5):1564-1569 
123. Domrongkitchaiporn S, Pongsakul C, Stitchantrakul W, Sirikulchayanonta V, 
Ongphiphadhanakul B, Radinahamed P, Karnsombut P, Kunkitti N, Ruang-raksa C, 
Rajatanavin R (2001) Bone mineral density and histology in distal renal tubular acidosis. 
Kidney Int 59 (3):1086-1093 
124. Disthabanchong S, Domrongkitchaiporn S, Sirikulchayanonta V, Stitchantrakul W, 
Karnsombut P, Rajatanavin R (2004) Alteration of noncollagenous bone matrix proteins in 
distal renal tubular acidosis. Bone 35 (3):604-613 
125. Domrongkitchaiporn S, Pongskul C, Sirikulchayanonta V, Stitchantrakul W, Leeprasert 
V, Ongphiphadhanakul B, Radinahamed P, Rajatanavin R (2002) Bone histology and bone 
mineral density after correction of acidosis in distal renal tubular acidosis. Kidney Int 62 
(6):2160-2166 
Page 3 of 33 
 
126. Nash MA, Torrado AD, Greifer I, Spitzer A, Edelmann CM, Jr. (1972) Renal tubular 
acidosis in infants and children. Clinical course, response to treatment, and prognosis. J Pediatr 
80 (5):738-748 
127. McSherry E, Morris RC, Jr. (1978) Attainment and maintenance of normal stature with 
alkali therapy in infants and children with classic renal tubular acidosis. J Clin Invest 61 
(2):509-527 
128. Preminger GM, Sakhaee K, Pak CY (1988) Alkali action on the urinary crystallization of 
calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol 139 (2):240-
242 
129. Greenberg AJ, McNamara H, McCrory WW (1966) Metabolic balance studies in primary 
renal tubular acidosis: effects of acidosis on external calcium and phosphorus balances. J 
Pediatr 69 (4):610-618 
130. Wikstrom B, Backman U, Danielson BG, Fellstrom B, Johansson G, Ljunghall S (1983) 
Ambulatory diagnostic evaluation of 389 recurrent renal stone formers. A proposal for clinical 
classification and investigation. Klin Wochenschr 61 (2):85-90 
131. Ito H, Kotake T, Suzuki F (1993) Incidence and clinical features of renal tubular acidosis-
1 in urolithiasis. Urol Int 50 (2):82-85 
132. Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky 
D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella 
M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, 
Williams JC (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and 
its systemic manifestations: a consensus statement. J Nephrol 29 (6):715-734 
133. Dhayat NA, Gradwell MW, Pathare G, Anderegg M, Schneider L, Luethi D, Mattmann C, 
Moe OW, Vogt B, Fuster DG (2017) Furosemide/Fludrocortisone Test and Clinical Parameters 
to Diagnose Incomplete Distal Renal Tubular Acidosis in Kidney Stone Formers. Clin J Am 
Soc Nephrol 12 (9):1507-1517 
134. Pak CY, Poindexter JR, Adams-Huet B, Pearle MS (2003) Predictive value of kidney stone 
composition in the detection of metabolic abnormalities. Am J Med 115 (1):26-32 
135. Pak CY, Poindexter JR, Peterson RD, Heller HJ (2004) Biochemical and physicochemical 
presentations of patients with brushite stones. J Urol 171 (3):1046-1049 
136. Zhang J, Fuster DG, Cameron MA, Quinones H, Griffith C, Xie XS, Moe OW (2014) 
Incomplete distal renal tubular acidosis from a heterozygous mutation of the V-ATPase B1 
subunit. Am J Physiol Renal Physiol 307 (9):F1063-1071 
137. Dhayat NA, Schaller A, Albano G, Poindexter J, Griffith C, Pasch A, Gallati S, Vogt B, 
Moe OW, Fuster DG (2016) The Vacuolar H+-ATPase B1 Subunit Polymorphism p.E161K 
Associates with Impaired Urinary Acidification in Recurrent Stone Formers. J Am Soc Nephrol 
27 (5):1544-1554 
138. Mohebbi N, Vargas-Poussou R, Hegemann SC, Schuknecht B, Kistler AD, Wuthrich RP, 
Wagner CA (2013) Homozygous and compound heterozygous mutations in the ATP6V1B1 
gene in patients with renal tubular acidosis and sensorineural hearing loss. Clin Genet 83 
(3):274-278 
139. Fuster DG, Zhang J, Xie XS, Moe OW (2008) The vacuolar-ATPase B1 subunit in distal 
tubular acidosis: novel mutations and mechanisms for dysfunction. Kidney Int 73 (10):1151-
1158 
 
Page 3 of 33 
 
TABLES 
Table 1.  Genetic disorders of the TALH associated with kidney stones. 
Gene  Mode of inheritance Clinical features 
Monogenetic Disease   
SLC12A1 Autosomal-recessive Bartter syndrome type I [64]. 
KCNJI Autosomal-recessive Bartter syndrome type II [63]. 
CLCNKB Autosomal recessive Bartter syndrome type III [65]. 
BSND Autosomal-recessive Bartter syndrome type IV [67]. 
CASR Autosomal-recessive Bartter syndrome type V [66]. 
CLDN16 Autosomal-recessive 
FHHNC [33]. Heterozygous CLDN16 mutations have been 
associated with hypercalciuria and nephrolithiasis in pedigree 
analyses [80,84,81]. 
CLDN19 Autosomal-recessive FHHNC with ocular involvement [34]. 
Variants   
CLDN14 
rs219780 
rs219781 
rs219778 
- 
Synonymous variants identified by GWAS associated with increased 
risk for kidney stones, low bone mass, increased urinary Ca and 
serum parathyroid hormone and reduced serum total CO2 in 
Icelandic and Dutch population [8]. Variants are also associated with 
increased risk for kidney stones but not with urinary Ca in Indian 
population [86]. No association found with urinary Ca in North 
American population [85]. 
CLDN14 
rs113831133 
- Non-synonymous variant (c.11C>T, p.Thr4Met) associated with reduced urinary Ca excretion in North American population [85]. 
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CASR 
rs1801725 
rs1042636 
rs1801726 
- 
Non-synonymous variants (p.A986S, p.R990G and p.Q1011E) in 
Exon 7 associated with increased risk for kidney stones and increased 
urinary Ca excretion [88,86,89]. 
CASR 
rs17251221  
rs1501899 
rs7652589 
- Intronic or 5’UTR variants associated with increased risk for kidney stones [86,89-94]. 
CASR 
rs7627468 
- 
Variant in a regulatory region of the first intron identified by GWAS 
associated with increased risk for kidney stones, increased serum 
total and ionized Ca and decreased 25-hydroxy vitamin D [7]. 
UMOD 
rs4293393 
- 
Variant identified by GWAS associated with increased risk for CKD 
and gout but reduced risk for kidney stones in Icelandic and Dutch 
population [95]. 
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Table 2.  Genetic disorders of the CNT associated with kidney stones. 
 
Gene  Mode of inheritance Clinical features 
Monogenetic Disease   
ATP6V1B1  Autosomal-recessive DRTA, early onset sensorineural hearing loss [97].  
ATP6V0A4  Autosomal-recessive DRTA, late onset sensorineural hearing loss [98]. 
SLC4A1 
Autosomal recessive or  
autosomal-dominant  
DRTA, hemolytic anemia (rare). Maybe incomplete dRTA in case of 
autosomal-dominant mutation [107]. 
FOXI1 Autosomal-recessive Early onset sensorineural hearing loss [99]. 
CAII Autosomal-recessive 
Mixed pRTA and dRTA. Intracerebral calcifications, psychomotor 
retardation, abnormal teeth with enamel hypoplasia, osteopetrosis in 
severe cases causing optic nerve entrapment and blindness [101]. 
Variants   
ATP6V1B1 
c.481G>A;p.E161K - 
Urinary acidification deficit, elevated urinary pH, increased 
prevalence of CaP containing kidney stones in heterozygous SF 
[137]. 
Overt dRTA in homozygous carriers of the variant (1 patient 
reported) or if compound heterozygous with other pathogenic 
ATP6V1B1 variant [11,138].  
ATP6V1B1 
c.1401_1402dupGT; 
p.F468fsX487 
- 
Urinary acidification deficit, elevated urinary pH, CaP containing 
kidney stones in heterozygous carriers [136]. 
Overt dRTA in homozygous carriers of the variant [139]. 
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FIGURES 
 
Figure 1. Schematic representation of a TALH cell. 
Abbreviations: NKCC2, Na-K-2Cl cotransporter; ROMK, renal outer medullary K channel; 
ClC-Kb, voltage-gated Cl channel Kb isoform ; KCC4, K-Cl cotransporter; CaSR, calcium-
sensing receptor. 
 
 
Figure 2. Schematic representation of a Type A intercalated cell. 
Abbreviations: AE1, anion exchanger 1; CAII, carbonic anhydrase type II; V, membrane-
anchored subunit of the V-ATPase; V, head subunit of the V-ATPase.  
